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Abstract
Background: The purpose of this study was to determine whether some of the clinical features of fibromyalgia (FM) 
that patients would like to see improved aggregate into definable clusters.
Methods: Seven hundred and eighty-eight patients with clinically confirmed FM and baseline pain ≥40 mm on a 100 
mm visual analogue scale ranked 5 FM clinical features that the subjects would most like to see improved after 
treatment (one for each priority quintile) from a list of 20 developed during focus groups. For each subject, clinical 
features were transformed into vectors with rankings assigned values 1-5 (lowest to highest ranking). Logistic analysis 
was used to create a distance matrix and hierarchical cluster analysis was applied to identify cluster structure. The 
frequency of cluster selection was determined, and cluster importance was ranked using cluster scores derived from 
rankings of the clinical features. Multidimensional scaling was used to visualize and conceptualize cluster relationships.
Results: Six clinical features clusters were identified and named based on their key characteristics. In order of selection 
frequency, the clusters were Pain (90%; 4 clinical features), Fatigue (89%; 4 clinical features), Domestic (42%; 4 clinical 
features), Impairment (29%; 3 functions), Affective (21%; 3 clinical features), and Social (9%; 2 functional). The "Pain 
Cluster" was ranked of greatest importance by 54% of subjects, followed by Fatigue, which was given the highest 
ranking by 28% of subjects. Multidimensional scaling mapped these clusters to two dimensions: Status (bounded by 
Physical and Emotional domains), and Setting (bounded by Individual and Group interactions).
Conclusion: Common clinical features of FM could be grouped into 6 clusters (Pain, Fatigue, Domestic, Impairment, 
Affective, and Social) based on patient perception of relevance to treatment. Furthermore, these 6 clusters could be 
charted in the 2 dimensions of Status and Setting, thus providing a unique perspective for interpretation of FM 
symptomatology.
Background
Chronic widespread pain is the primary characteristic of
FM. Its presence is the essential feature of the current
American College of Rheumatology guidelines for the
classification of FM [1] and it is the best understood fea-
ture of this syndrome [2,3]. In addition to pain, FM
patients typically exhibit a number of co-morbidities that
limit productivity, personal and family life, and activities
of daily living [4-8]. These comorbidities may include
fatigue, sleep disturbance, mood disorders, cognitive
impairment, restless legs, balance problems, recurrent
headaches, irritable bowel, and overactive bladder [9].
This heterogeneity has contributed to difficulty in char-
acterizing the inter-relationships among FM clinical fea-
tures and in determining the importance of various
comorbidities to patients and their treatment outcomes.
Cluster analysis is a multivariate statistical technique
that can be used for evaluating the degree of similarity
among apparently heterogeneous variables, and identify-
ing related groups of variables based on these similarities.
The concept of identifying clusters of patient-relevant
clinical features through cluster analysis has become
important in the oncology setting as a tool for developing
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patient orientated management strategies [10,11]. This
concept has been applied to other disorders in an effort to
understand the relationships among clinical features and
outcome variables [12-14].
Cluster analysis has also been applied to FM in several
studies [15-20]. While some of these studies categorized
patients through the use of objective quantitative sensory
testing [15] and psychophysiologic response patterns
[18], others identified subgroups based on the presence
and severity of physical and/or affective clinical features
[16,19,20]. In contrast to these studies, which have used
cluster analysis to identify patient clusters (i.e., groups of
patients with similar characteristics), we have attempted
to identify clusters of clinical features that are meaningful
to FM patients and correspond to their treatment priority
goals in the context of desired improvement.
In several ways, a cluster analysis based on clinical fea-
tures extends beyond a cluster analysis of patients who
share a similar clinical profile. This type of analysis
directly targets, aggregates, and identifies those clinical
features that are related (i.e. cluster together); quantifies
the importance of each cluster (i.e., which clusters are
more clinically relevant); and allows interpretation of
clusters with respect to their perceptual relationships and
key attributes (i.e., what characterizes the different clus-
ters).
As part of an approach to understanding the relation-
ships among the clinical features of FM, we focused on
identifying those features that patients would most like to
be improved as a result of treatment, and then aggregated
those preferences into clusters. The study reported here
describes a cluster analysis algorithm for identifying
patient-relevant groups of closely-related clinical fea-
tures. The intent of this exercise is to: 1) promote a better
understanding of FM through grouping clinical features
(rather than individual features in isolation), and 2) char-
acterize key clusters that may facilitate the assessment
and management of FM.
Methods
This study is a secondary analysis using baseline data of
patients with FM, before randomization to either pregab-
alin or placebo, who were entered into a double-blind pla-
cebo-controlled randomized clinical trial of pregabalin.
Details of the trial and the treatment groups have previ-
ously been published [21]. As this was a secondary analy-
sis, research subjects' anonymity was preserved and an
ethical committee approval was not required; the study
was conducted in accordance with the Declaration of
Helsinki. All subjects met the 1990 ACR definition for
FM [1] and had a pain rating ≥40 mm on a 100 mm visual
analogue scale (VAS). They were asked to identify 5 FM
clinical features, from a list of 20 distinct clinical features,
which they would most like to see improved after treat-
ment. The list of clinical features used in this study was
developed during patient focus groups that were con-
ducted to elicit concepts relevant to assessing the impact
of FM on their lives [22].
After identifying the 5 clinical features, subjects then
assigned each clinical feature a relative importance by
arranging them in order within five priority quintiles. The
rationale for choosing, a priori, the top 5 clinical features
comes from the demonstration in cognitive psychology
that the upper limit of categories that individuals can dis-
criminate is near 7 plus or minus 2 [23,24].
Distance Matrix
The analysis was initiated by representing each subject by
a vector of 20 values (one for each clinical feature), with
the rankings assigned values of 1-5 (lowest to highest
r a n k i n g ;  c l i n i c a l  f e a t u r e s  n o t  c h o s e n  w e r e  a s s i g n e d  a
value of 0) for the 5 most important FM clinical features.
W e  b e g a n  t o  f o r m a l l y  e v a l u a t e  t h e  r e l a t i o n s h i p s
between the clinical features by using logistic regression
[25] to predict the likelihood of selecting each clinical fea-
ture based on the selection of another clinical feature, and
thus deriving an odds ratio for the likelihood of each pair
of features being co-selected. This method essentially
created a distance matrix between the pairs based on
rankings. For example, the clinical feature "pain or dis-
comfort" (item 15) and the clinical feature "disturbed
sleep" (item 16) can then be used to create a 2-by-2 cross-
classification table to quantify the relationship between
them: 1 means that the clinical feature was selected
among a subject's five most important clinical features,
and 0 means that it was not ranked in the top five.
The odds ratio of having selected a second variable
after a particular first variable was calculated for all possi-
ble pair-wise combinations of clinical features to define
the relative distance between co-selected variables. The
inverse or reciprocal of each of the resulting odds ratios
was then calculated (so that a smaller odds ratio would be
represented by a greater distance) to serve as proxies to
define distances between clinical features as input into
the distance matrix between the pairs in the cluster analy-
sis.
Cluster Analysis
Based on the distance matrix between pairs of clinical
features, a hierarchical cluster analysis [26] was the algo-
rithm applied to identify cluster structure. This hierarchi-
cal cluster analysis was used to group together clinical
features that are "close to one another" into a cluster such
that those clinical features within each cluster are more
closely related to one another than clinical features
assigned to different clusters. In hierarchical clustering, a
major method of clustering, the data are not partitioned
into a particular cluster in a single step. Instead, a seriesBennett et al. BMC Musculoskeletal Disorders 2010, 11:134
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of partitions takes place, which may run from a single
cluster containing all clinical features to many clusters,
each containing a single clinical feature.
Based on the cluster algorithm, a dendogram was gen-
erated for visual classification of similarity for grouping
the clinical features. In the dendogram, the clinical fea-
tures were represented as nodes and the branches illus-
trated when the cluster method joined subgroups of
clinical features. The length of the branch indicated the
distance between the subgroups of clinical features when
they were joined. The cluster analysis also identified clus-
ters of those clinical features concurrently selected by the
subjects. The frequency of cluster selection was deter-
mined and cluster importance was ranked. Cluster
importance score was defined by the selection frequen-
c i e s  o f  t h e  i n d i v i d u a l  c l i n i c a l  f e a t u r e s  a d j u s t e d  f o r  t h e
number of clinical features in a cluster.
Multidimensional Scaling
Multidimensional scaling is a multivariate statistical tech-
nique often used to visualize information for exploring
similarities or dissimilarities in data [27], and it was uti-
lized here to discern and explore the similarities and dis-
similarities among the clinical features. Based on the
distance between clinical features in the cluster analysis,
multidimensional scaling was applied to characterize the
perceptual relationship among clusters, and to provide
insight and interpretation to the clusters by presenting
and relating them in terms of meaningful and under-
standable descriptors. The names that were eventually
given to each of the clusters were determined post-hoc in
an attempt to characterize the nature of each cluster in
perceptual space. In doing so, the geometric results from
the multidimensional scaling, which provided a percep-
tual map but no clusters, were used to complement and
enhance the results of the cluster analysis, which pro-
vided clusters but no perceptual map.
All analyses were performed in SAS®, including its pro-
cedures PROC LOGISTIC, PROC CLUSTER and PROC
MDS [28].
Results
Rankings from a total of 788 subjects were surveyed. The
subjects were predominantly female (95%), with a mean
age of 50 years and a mean duration of FM of 10 years. Of
the 788 subjects, 34 (4.3%) chose not to rank clinical fea-
tures and were assigned rankings of zero for all 20 items.
The 20 clinical features and the proportion of subjects
ranking their importance are shown in Table 1. Pain was
ranked as the most important clinical feature by the
greatest proportion of subjects (43.9%). It was followed in
the first priority quintile by lack of energy (17%), dis-
turbed sleep (10%), feeling tired (6%), and difficulty
thinking (5%). The clinical features ranked as second in
importance (second quintile) were disturbed sleep (21%),
followed by lack of energy (17%), pain or discomfort
(15%), feeling tired (15%) and difficulty thinking (6%).
Since the two clinical features ranked overall as first
and second in importance were respectively "pain or dis-
comfort" (q15) and "disturbed sleep" (q16), it is illustra-
tive to note how their relationship was determined for use
in the cluster analysis. Those two clinical features were
each selected in the top five by 401 patients (these
patients were scored 1 for "pain or discomfort" and 1 for
"disturbed sleep"). Neither of these two features was
selected in the top five by 91 patients (these patients were
scored 0 for "pain or discomfort" and 0 for "disturbed
sleep"). "Pain or discomfort" was selected in the top five
but disturbed sleep was not selected in the top 5 by 229
patients (these patients scored 1 for "pain or discomfort"
and 0 for "disturbed sleep") while the reverse occurred in
67 patients (these patients were scored 0 for "pain or dis-
comfort" and 1 for "disturbed sleep"). Therefore, the odds
of having selected "pain or discomfort," if "disturbed
sleep" was selected, is 401*91/229*67, or approximately
2.4-times as likely relative to "disturbed sleep" not being
selected. The relationships for other pairs of clinical fea-
tures were similarly assessed for input into the distance
matrix in the cluster analysis.
Clustering identified 6 distinct groups, with each clus-
ter having several related clinical features (Figure 1).
These six clusters were named on the basis of their key
characteristics. They included the following: 1) "Fatigue"
(composed of clinical features q1, q2, q6, and q9), 2)
"Social" (clinical features q10 and q11), 3) "Impairment"
(clinical features q3, q7, and q12), 4) "Domestic" (clinical
features q4, q5, q17, and q19), 5) "Affective" (clinical fea-
tures q8, q14, and q18), and 6) "Pain" (clinical features
q13, q15, q16, and q20).
Multidimensional scaling performed on the distance
between clinical features confirmed the conceptual valid-
ity of the proposed clusters and provided a graphic repre-
sentation of how the clusters are perceptually related
(Figure 2). As shown in Figure 2, the conceptual map
shows patient perceptions of the 20 clinical features
grouped into six distinct clusters that spread across two
dimensions. These dimensions were defined as "Setting"
(vertical axis, bounded by group and individual interac-
tions) and "Status" (horizontal axis, bounded by physical
and emotional domains). This two-dimensional configu-
ration was found to be statistically and substantially suffi-
cient in accordance with the goal of emphasizing a
parsimonious and substantive interpretation consistent
with a rigorous empirical analysis. Calculations using
three or more dimensions did not improve the fit of the
model.
For example, the analysis suggested that this sample of
patients felt that clinical features in the Social clusterB
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Table 1: Ranking of treatment-relevant clinical features among 788 fibromyalgia patients*
Symptom Number Symptom Rank order by importance, n (%) Priority Quintiles
1st 2nd 3rd 4th 5th Not ranked
q1 Having a lack of energy 126 (16.0) 129 (16.4) 106 (13.5) 70 (8.9) 68 (8.6) 289 (36.7)
q2 Having to push yourself to do things 18 (2.3) 39 (4.9) 69 (8.8) 67 (8.5) 65 (8.3) 530 (67.3)
q3 Interference with your ability to accomplish daily tasks, such as 
housework or shopping
16 (2.0) 16 (2.0) 42 (5.3) 41 (5.2) 52 (6.6) 621 (78.8)
q4 Impact on your family 33 (4.2) 17 (2.2) 20 (2.5) 26 (3.3) 29 (3.9) 663 (84.1)
q5 Difficulty being sexually intimate with your partner 9 (1.1) 15 (1.9) 24 (3.1) 30 (3.8) 29 (3.7) 681 (86.4)
q6 Feeling tired 43 (5.5) 111 (14.1) 111 (14.1) 95 (12.1) 61 (7.7) 367 (46.6)
q7 Interference with work or school 11 (1.4) 6 (0.8) 17 (2.2) 21 (2.7) 22 (2.8) 711 (90.2)
q8 Feeling anxious 2 (0.3) 9 (1.1) 3 (0.4) 14 (1.8) 17 (2.2) 743 (94.3)
q9 Difficulty thinking or "fibro fog" 37 (4.7) 44 (5.6) 62 (7.9) 89 (11.3) 68 (8.6) 488 (61.9)
q10 Feeling like the pace of your life is slower than most other people 1 (0.1) 8 (1.0) 7 (0.9) 10 (1.3) 15 (1.9) 747 (94.8)
q11 Impact on your social life 1 (0.1) 4 (0.5) 5 (0.6) 10 (1.3) 16 (2.0) 752 (95.4)
q12 Driving limitations 0 1 (0.1) 1 (0.1) 0 5 (0.6) 781 (99.1)
q13 Skin is sensitive to touch 6 (0.8) 12 (1.5) 16 (2.0) 25 (3.1) 34 (4.3) 695 (88.2)
q14 Feeling depressed 11 (1.4) 15 (1.9) 21 (2.7) 31 (3.9) 29 (3.7) 681 (86.4)
q15 Pain or discomfort 329 (41.8) 116 (14.7) 80 (10.2) 62 (7.9) 43 (5.5) 158 (20.1)
q16 Disturbed sleep 71 (9.0) 159 (20.2) 103 (13.1) 77 (9.8) 58 (7.4) 320 (40.6)
q17 Strain on your relationship with your spouse 8 (1.0) 10 (1.3) 16 (2.0) 13 (1.7) 23 (2.9) 718 (91.1)
q18 Feeling isolated or alone 2 (0.3) 1 (0.1) 6 (0.8) 8 (1.0) 21 (2.7) 750 (95.2)
q19 Being unable to make plans with the confidence that you will follow-
through
5 (0.6) 16 (2.0) 16 (2.0) 19 (2.4) 55 (7.0) 677 (85.9)
q20 Difficulty walking 19 (2.4) 22 (2.8) 27 (3.4) 43 (5.5) 40 (5.1) 637 (80.8)
* The left column indicates the question number while the second column provides an abstraction of the original question regarding a specific clinical feature. The five columns to the right 
contain the number and proportion of subjects who ranked that question as 1st, 2nd, 3rd, 4th or 5th in importance, respectively.Bennett et al. BMC Musculoskeletal Disorders 2010, 11:134
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(bottom right) impinged on group-oriented activities and
had the highest emotional consequence. Symptoms in the
Domestic cluster (bottom center) were perceived as
adversely affecting group interaction the most and
impacting both physical and emotional factors. Symp-
toms in the Fatigue cluster (top) were rated as being most
intrusive to the individual and having both physical and
emotional implications. Symptoms in the Impairment
cluster (center) were thought to interfere with physical
activities, have emotional impact, and affect group inter-
actions. Symptoms in the Affective cluster (center right)
occurred in both individual and group settings with sub-
stantial emotional consequences. Symptoms in the Pain
cluster (top left) compromised the individual with pre-
dominantly physical limitations.
A complementary way to interpret Figure 2 is in terms
of cluster similarity and dissimilarity. For example, clini-
cal features of Fatigue were in closer proximity--and
hence more related--to clinical features of Pain than to
clinical features covering Domestic issues.
The clusters most frequently chosen, based on the clus-
ter importance score greater than 0, were those related to
the physical domains (Table 2). Symptoms contained
within the Pain Cluster were selected by 90.1% of sub-
jects, closely followed by those in the Fatigue Cluster
(89.3%). The most commonly endorsed psychosocial
domain cluster was Domestic (42.0%), followed by Affec-
tive (20.9%); the Social Cluster was selected by only 9.3%
of subjects. In addition to being the most frequently
invoked cluster, the Pain Cluster was also ranked the
most important cluster by the highest proportion of
patients (53.9%), and ranked second in importance by
another 14.7% of subjects (Table 2). In contrast, the
Fatigue Cluster was ranked as first and second most
important by an approximately equal proportion of
patients (28.4% and 27.9%, respectively). The psychoso-
cial domain clusters (Affective, Domestic, and Social)
were more likely to be selected as the least important
clusters.
Discussion
The multidimensional nature of FM obscures our under-
standing of the burden of FM in individual patients and
complicates the development of appropriate comprehen-
sive management strategies. Understanding the full com-
plexity of the clinical features of FM is becoming
Figure 1 Dendogram from the cluster analysis of the 20 clinical features. The dendrogram was generated using odds ratios (i.e. likelihood of pairs 
of symptoms being co-selected) as a proxy for distance between symptoms. A description of each clinical feature by number is presented in Table 1.Bennett et al. BMC Musculoskeletal Disorders 2010, 11:134
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increasingly important with the availability of newer
pharmacologic therapies that have significant effects on
pain and other clinical features such as sleep (pregabalin
[21], sodium oxybate [29,30]), affective symptoms (dulox-
etine [31,32]), and fatigue and cognitive function (mil-
nacipran [33]. Additionally, recent proposals suggesting
the use of combination therapies [34-36] warrant a more
complete understanding of the relationships among clini-
cal features from the patient perspective.
The approach described here measured the strength of
the relationship among the 20 clinical features that FM
pa t ie n ts w oul d most  lik e  t o be  im pr o ved during t r ea t -
Figure 2 Multidimensional scaling map of the conceptual relationships among the clusters of clinical features. The conceptual map shows 
patient perceptions of the 20 clinical features divided into 6 distinct clusters on the dimensions of Setting, bounded by Group and Individual interac-
tions on the vertical axis, and Status, bounded by Physical and Emotional domains on the horizontal axis. The items in each cluster were determined 
by the odds ratio of each item being co-selected by fibromyalgia patients as being important to their care. The relative location of each cluster iden-
tifies its dimensional relationship. For example, the Pain cluster would be considered strong with regard to Individual effects and the Physical domain, 
while the Domestic cluster would be strongly Group-related but would have roots in both Physical and Emotional domains.Bennett et al. BMC Musculoskeletal Disorders 2010, 11:134
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ment. It was found that these clinical features could be
categorized into 6 clusters. Furthermore, these clusters
could be mapped in the two dimensions of Status (hori-
zontal axis, bounded by physical and emotional domains)
and Setting (vertical axis, bounded by group and individ-
ual interactions). These 2 dimensions represent how
patients perceive the impact of their clinical features with
respect to emotional and physical consequences (Status),
as well as whether they affect individual or group interac-
tions (Setting). Not surprisingly, these clusters are similar
to the four domains of physical, cognitive/emotional,
social, and work/activity, identified during the focus
groups which served as the foundation for developing the
20 clinical features for ranking [22]. However, in contrast
to the focus groups, our cluster analysis identified Pain
and Fatigue as independent clusters. The Pain Cluster
was predominantly associated with the physical domain,
while the Fatigue Cluster had both physical and emo-
tional components. The Impairment Cluster, which
relates to an FM-related inability to perform daily tasks,
was also identified as being independent from the other 5
clusters.
Interestingly, "Disturbed sleep (q9)" clustered with pain
rather than fatigue. While pain and sleep have been sug-
gested to have a reciprocal relationship in chronic pain
conditions including FM [37-39], our results raise the
question as to whether pain causes disturbed sleep or
pain is a result of disturbed sleep, as originally proposed
by Moldofsky et al. [40] and further supported by recent
studies [41,42]. Of similar interest, "Difficulty thinking or
fibro-fog (q9)" clustered with the physical domain cluster
of Fatigue. Although the significance of this clustering is
presently unclear , it is noteworthy that Katz et al. [43]
r e p o r t e d  a n  a s s o c i a t i o n  o f  " f i b r o f o g "  w i t h  i n c r e a s e d
symptom intensity in terms of pain, stiffness, fatigue, and
disturbed sleep.
Our use of cluster analysis to identify clinical features
clusters is in contrast to other studies which used the
same technique to identify patient clusters [15-20]. While
these two approaches can provide complementary infor-
mation that can aid in our understanding of FM, clinical
features clusters may provide a more clinically relevant
approach since current management goals are clinical
features-driven.
The concept of ranking FM treatment goals has previ-
ously been explored using cluster analysis in a study by
Hamilton et al. [17]. They identified 3 subgroups based
on the patients' ranking of FM-specific goals. These sub-
groups included seeking professional care, which may
correlate to the physical domain clusters and the Affec-
tive cluster in the current study; self-sufficiency goals,
which may correlate with our Impairment cluster; and
social-validation goals, which likely correlates with the
those clusters affecting group interactions. Their demon-
s t r a t i o n  t h a t  g o a l  p r o f i l e s  c o v a r i e d  w i t h  d i f f e r e n c e s  i n
pain, negative affect, goal-specific social support, general
social support, goal-related interference, and negative life
events provide further support for the use of clinical fea-
tures clusters as another means of determining patient
priorities.
Although the frequency with which the Pain cluster
and Fatigue cluster were identified by subjects as being
important was comparable, the Pain cluster was selected
as most important by 54% of subjects, consistent with
pain being the hallmark clinical feature of FM [1]. The
Fatigue cluster was selected as most important by 28% of
subjects, but the psychosocial clusters were not consid-
ered to be as high a priority, with ≥70% of subjects not
giving them a ranking.
A recent study that used exploratory factor analysis to
evaluate correlations among 20 symptoms reported by
patients with FM suggested that 17 of these symptoms
Table 2: Selection and ranking frequency of treatment-relevant clusters of clinical features.*
Cluster Selection frequency,
% of subjects
Ranking frequency, % of subjects
12345 N o t  r a n k e d
Pain 90.1 53.9 14.7 11.6 6.5 3.4 9.9
Fatigue 89.3 28.4 27.9 20.9 8.0 4.1 10.7
Domestic 42.0 7.0 6.0 8.1 7.7 13.2 58.0
Impairment 29.1 3.4 2.7 7.2 7.0 8.8 70.9
Affective 20.9 1.9 2.9 3.3 6.1 6.7 79.1
Social 9.3 0.3 1.5 1.5 2.0 3.9 90.7
*For frequency, cluster was marked as selected if at least one clinical feature from this cluster was chosen. Ranking was determined based on 
the maximum number of clinical features scored from every cluster.Bennett et al. BMC Musculoskeletal Disorders 2010, 11:134
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partition into 5 factors or clusters: Somatic (extremity
swelling, rashes, restless legs, abdominal pain, bladder
problems, muscle spasms), Distress (anxiety, depression),
FM Core (morning stiffness, pain, fatigue), Dyscognition
(postural instability, dizziness, concentration problems,
forgetfulness), and Sleep Problems (inability to fall asleep,
inability to stay asleep) [44]. However, that study was sub-
stantially different from ours not only in their use of fac-
tor analysis rather than cluster analysis, but also with
regard to their perspective in choice of symptoms. In
contrast to the current study, which utilized a patient per-
spective, they took a more clinical perspective by choos-
ing symptoms that were reported as being present among
a surveyed population of patients with FM. Additionally,
they used symptom severity as the basis for their correla-
tion analysis, which probably accounts for their reported
grouping of symptoms within cluster; the presence and
severity of a particular symptom may not necessarily
equate with patients' preferences for its treatment.
Because of limitations inherent in our investigation,
care and context should be exercised in interpreting the
results of this study. Some of these limitations are repre-
sented by the inclusion/exclusion criteria, which can be
construed as limiting the application of our results to the
more general clinical FM population. In particular, there
was an inclusion requirement for a minimum pain sever-
ity score, and a criterion of exclusion for subjects with
major depressive disorder. However, not only is the pain
requirement consistent with clinical studies evaluating
new FM therapies, but pain is the major clinical feature of
FM, and despite inter-patient variability in pain severity
scores [45], a mean pain score of 6.4 ± 2.0 has been
reported from FM subjects in the general population [9],
suggesting that the minimum severity level required for
this study is not an unreasonable expectation in clinical
practice. Although subjects with major depressive disor-
der were excluded, depression is present in about 34% of
FM patients [46]. In the current population, baseline
scores of score 8.7 ± 4.2 for anxiety and 7.1 ± 4.1 for
depression on the Hospital Anxiety and Depression Scale,
indicated the presence of at least mild depression and
anxiety [21].
The input for the cluster analysis was derived from the
relative importance of the five most bothersome clinical
features that a subject would like to see addressed after
entry into an industry-supported pharmacologic study.
This aspect of the study may be criticized as a limitation,
since patients' expectations with regard to their treatment
in a clinical trial could have potentially introduced bias in
their responses. Nevertheless, given that the chosen clini-
cal features stem from those documented as having a sub-
stantial negative impact on daily life, based on focus
groups [22], the same selection of clinical features would
likely be made if patients were simply asked about the
most problematic clinical features they experience. Our
findings document and quantify that pain is the most
prominent clinical feature for FM patients, with fatigue
being the next most problematic symptom; this confirms
the findings of other studies [20,47,48].
Of note, stiffness, which has recently been recognized
as an important symptom for FM patients [47], albeit not
as part of the core or secondary domains required for
assessment in clinical trials [49], does not appear in any of
our identified clusters. The reason for this omission is
that stiffness, despite being of clinical importance, was
not among those clinical features identified as being of
high relevance to patients in the focus groups [22], and
was thus omitted from the list of 20 clinical features pre-
sented to the subjects in the current study.
Ongoing study of multiple clinical features within and
between clusters will yield empirical confirmation or ref-
utation on the existence and extent of these clusters. For
instance, a recent factor analysis of musculoskeletal, non-
musculoskeletal, and cognitive/psychological domains
derived from the National Fibromyalgia Association
patient survey revealed 4 distinctive clusters [50]. Cluster
1 was high on all 3 domains, cluster 2 was moderate on
musculoskeletal/non-musculoskeletal domains and high
on cognitive/psychological domains, cluster 3 was mod-
erate on the musculoskeletal/non-musculoskeletal
domains and low on the cognitive/psychological domain,
and cluster 4 was low on all 3 domains. It was concluded
that the reporting of clinical features in FM patients is
quite variable, and that increased understanding of sub-
groups in relation to disease mechanisms may provide
useful guidance for treatment decisions.
Conclusion
This study characterizes the distinctive clustering of clin-
ical features that FM patients would like to see improved.
These clinical features grouped into 6 clusters with two
separate clusters, Pain and Fatigue, being the most fre-
quently invoked clusters. While both clusters impacted
the individual, Pain was related to the physical domain
and Fatigue spread across physical and emotional
domains. Pain and Fatigue were given the highest ranking
in importance by the greatest proportion of patients: 54%
for the Pain Cluster and 28% for the Fatigue Cluster. Fur-
ther evaluation is warranted to determine the clinical rel-
evance of clinical features clusters to the diagnosis and
treatment of fibromyalgia.
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